Volumetric analysis of IDH-mutant lower-grade glioma: A natural history study of tumor growth rates before and after treatment Journal Article

   

Authors:	Huang, R. Y.; Young, R. J.; Ellingson, B. M.; Veeraraghavan, H.; Wang, W.; Tixier, F.; Um, H.; Nawaz, R.; Luks, T.; Kim, J.; Gerstner, E. R.; Schiff, D.; Peters, K. B.; Mellinghoff, I. K.; Chang, S. M.; Cloughesy, T. F.; Wen, P. Y.
Article Title:	Volumetric analysis of IDH-mutant lower-grade glioma: A natural history study of tumor growth rates before and after treatment
Abstract:	Background: Lower-grade gliomas (LGGs) with isocitrate dehydrogenase 1 and/or 2 (IDH1/2) mutations have long survival times, making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and after treatment with established glioma therapies to determine whether a significant change in growth rate could be documented and perhaps be used in the future to evaluate treatment response to investigational agents in LGG trials. Methods: In this multicenter retrospective study, 230 adult patients with IDH1/2 mutated LGGs (World Health Organization grade II or III) undergoing surgery, radiation, or chemotherapy for progressive non-enhancing tumor were identified. Subjects were required to have 3 MRI scans containing T2/fluid attenuated inversion recovery imaging spanning a minimum of 6 months prior to treatment. A mixed-effect model was used to estimate tumor growth prior to treatment. A subset of 95 patients who received chemotherapy, radiotherapy, or chemoradiotherapy and had 2 posttreatment imaging time points available were evaluated for change in pre- and posttreatment volumetric growth rates using a piecewise mixed model. Results: The pretreatment volumetric growth rate across all 230 patients was 27.37%/180 days (95% CI: [23.36%, 31.51%]). In the 95 patients with both pre- and posttreatment scans available, there was a significant difference in volumetric growth rates before (26.63%/180 days, 95% CI: [19.31%, 34.40%]) and after treatment (-15.24% /180 days, 95% CI: [-21.37%, -8.62%]) (P < 0.0001). The growth rates for patient subgroup with 1p/19q codeletion (N = 118) was significantly slower than the rate of the 1p/19q non-codeleted group (N = 68) (22.84% vs 35.49%, P = 0.0108). Conclusion: In this study, we evaluated the growth rates of IDH mutant gliomas before and after standard therapy. Further study is needed to establish whether a change in growth rate is associated with patient survival and its use as a surrogate endpoint in clinical trials for IDH mutant LGGs. © 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Keywords:	adolescent; adult; cancer chemotherapy; treatment response; aged; cancer surgery; gene mutation; major clinical study; gene deletion; conference paper; cancer radiotherapy; temozolomide; nuclear magnetic resonance imaging; glioma; cancer grading; evidence based medicine; gene; tumor volume; retrospective study; world health organization; tumor growth; volume; mri; chromosome 1p; growth rate; idh; isocitrate dehydrogenase 1; chromosome 19q; idh1 gene; idh2 gene; isocitrate dehydrogenase 2; human; male; female; lgg; lower grade gliomas
Journal Title:	Neuro-Oncology
Volume:	22
Issue:	12
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2020-12-01
Start Page:	1822
End Page:	1830
Language:	English
DOI:	10.1093/neuonc/noaa105
PUBMED:	32328652
PROVIDER:	scopus
PMCID:	PMC7746936
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098742321&doi=10.1093%2fneuonc%2fnoaa105&partnerID=40&md5=9dd0ba0770ade40aa0efbae54231c6b3
Notes:	Conference Paper -- Export Date: 1 February 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/176037